{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:24:41Z","timestamp":1648819481601},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00292-013-1865-z","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T12:00:44Z","timestamp":1383739244000},"page":"214-220","source":"Crossref","is-referenced-by-count":0,"title":["Findet die molekulare Diagnostik Einzug in die Pankreaspathologie?"],"prefix":"10.1007","volume":"34","author":[{"given":"B.","family":"Sipos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sperveslage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,8]]},"reference":[{"key":"1865_CR1","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"Jones","year":"2008","unstructured":"Jones S et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801\u20131806","journal-title":"Science"},{"key":"1865_CR2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"Biankin","year":"2012","unstructured":"Biankin AV et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399\u2013405","journal-title":"Nature"},{"key":"1865_CR3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nature09460","volume":"467","author":"Campbell","year":"2010","unstructured":"Campbell PJ et al (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109\u20131113","journal-title":"Nature"},{"key":"1865_CR4","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1158\/1078-0432.CCR-12-1215","volume":"18","author":"Yachida","year":"2012","unstructured":"Yachida S et al (2012) Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res 18:6339\u20136347","journal-title":"Clin Cancer Res"},{"key":"1865_CR5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.canlet.2012.10.005","volume":"328","author":"McCleary-Wheeler","year":"2013","unstructured":"McCleary-Wheeler AL et al (2013) Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett 328:212\u2013221","journal-title":"Cancer Lett"},{"key":"1865_CR6","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Mancera PA et al (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. doi: 10.1038\/nature11114","DOI":"10.1038\/nature11114"},{"key":"1865_CR7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/bmm.12.69","volume":"6","author":"Kaur","year":"2012","unstructured":"Kaur S, Baine MJ, Jain M et al (2012) Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med 6:597\u2013612","journal-title":"Biomark Med"},{"key":"1865_CR8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nrc3420","volume":"13","author":"Klein","year":"2013","unstructured":"Klein AP (2013) Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 13:66\u201374","journal-title":"Nat Rev Cancer"},{"key":"1865_CR9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.gastro.2012.01.005","volume":"142","author":"Canto","year":"2012","unstructured":"Canto MI et al (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142:796\u2013804 (quiz e14\u2013e15)","journal-title":"Gastroenterology"},{"key":"1865_CR10","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","volume":"142","author":"Kanda","year":"2012","unstructured":"Kanda M et al (2012) Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142:730\u2013733.e9","journal-title":"Gastroenterology"},{"key":"1865_CR11","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1053\/j.gastro.2005.03.006","volume":"128","author":"Yan","year":"2005","unstructured":"Yan L et al (2005) Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128:2124\u20132130","journal-title":"Gastroenterology"},{"key":"1865_CR12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gutjnl-2012-302823","volume":"62","author":"Kanda","year":"2012","unstructured":"Kanda M et al (2012) Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 62:1024\u20131033","journal-title":"Gut"},{"key":"1865_CR13","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/annonc\/mdr617","volume":"23","author":"Bachet","year":"2012","unstructured":"Bachet JB et al (2012) Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol 23:2327\u20132335","journal-title":"Ann Oncol"},{"key":"1865_CR14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MPA.0b013e318247d6af","volume":"41","author":"Singh","year":"2012","unstructured":"Singh P, Srinivasan R, Wig JD (2012) SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 41:541\u2013546","journal-title":"Pancreas"},{"key":"1865_CR15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/SLA.0b013e3182827a65","volume":"258","author":"Oshima","year":"2013","unstructured":"Oshima M et al (2013) Immunohistochemically detected expression of 3 major genes (CDKN2A\/p16, TP53, and SMAD4\/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 258:336\u2013346","journal-title":"Ann Surg"},{"key":"1865_CR16","doi-asserted-by":"crossref","first-page":"e1000307","DOI":"10.1371\/journal.pmed.1000307","volume":"7","author":"Stratford","year":"2010","unstructured":"Stratford JK et al (2010) A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med 7:e1000307","journal-title":"PLoS Med"},{"key":"1865_CR17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"Collisson","year":"2011","unstructured":"Collisson EA et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17:500\u2013503","journal-title":"Nat Med"},{"key":"1865_CR18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00109-011-0832-5","volume":"90","author":"Gress","year":"2012","unstructured":"Gress TM et al (2012) Differentiation of multiple types of pancreatico-biliary tumors by molecular analysis of clinical specimens. J Mol Med Berl Ger 90:457\u2013464","journal-title":"J Mol Med Berl Ger"},{"key":"1865_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","volume":"136","author":"Farrell","year":"2009","unstructured":"Farrell JJ et al (2009) Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136:187\u2013195","journal-title":"Gastroenterology"},{"key":"1865_CR20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.2010.03838.x","volume":"71","author":"Gusella","year":"2011","unstructured":"Gusella M et al (2011) Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol 71:437\u2013444","journal-title":"Br J Clin Pharmacol"},{"key":"1865_CR21","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/1078-0432.CCR-08-2080","volume":"15","author":"Mar\u00e9chal","year":"2009","unstructured":"Mar\u00e9chal R et al (2009) Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 15:2913\u20132919","journal-title":"Clin Cancer Res"},{"key":"1865_CR22","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/j.gastro.2012.06.006","volume":"143","author":"Mar\u00e9chal","year":"2012","unstructured":"Mar\u00e9chal R et al (2012) Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143:664\u2013674.e1\u20136","journal-title":"Gastroenterology"},{"key":"1865_CR23","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"Von","year":"2011","unstructured":"Von Hoff DD et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol 29:4548\u20134554","journal-title":"J Clin Oncol"},{"key":"1865_CR24","doi-asserted-by":"crossref","first-page":"905091","DOI":"10.1155\/2013\/905091","volume":"2013","author":"Cucinotto","year":"2013","unstructured":"Cucinotto I et al (2013) Nanoparticle albumin bound paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv 2013:905091","journal-title":"J Drug Deliv"},{"key":"1865_CR25","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"Conroy","year":"2011","unstructured":"Conroy T et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825","journal-title":"N Engl J Med"},{"key":"1865_CR26","doi-asserted-by":"crossref","unstructured":"Heinemann V, Haas M, Boeck S (2013) Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol. doi: 10.1093\/annonc\/mdt239","DOI":"10.1093\/annonc\/mdt239"},{"key":"1865_CR27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/PPO.0b013e3182758985","volume":"18","author":"Cinar","year":"2012","unstructured":"Cinar P, Tempero MA (2012) Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J 18:653\u2013664 (Sudbury Mass)","journal-title":"Cancer J"},{"key":"1865_CR28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4614-6176-0_5","volume":"779","author":"Yee","year":"2013","unstructured":"Yee NS (2013) Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype. Adv Exp Med Biol 779:91\u2013143","journal-title":"Adv Exp Med Biol"},{"key":"1865_CR29","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"Moore","year":"2007","unstructured":"Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"key":"1865_CR30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/gutjnl-2012-302759","volume":"62","author":"Heinemann","year":"2013","unstructured":"Heinemann V et al (2013) Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the \u201aArbeitsgemeinschaft Internistische Onkologie\u2018 (AIO-PK0104). Gut 62:751\u2013759","journal-title":"Gut"},{"key":"1865_CR31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bjc.2012.495","volume":"108","author":"Boeck","year":"2013","unstructured":"Boeck S et al (2013) EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer 108:469\u2013476","journal-title":"Br J Cancer"},{"key":"1865_CR32","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00535-013-0767-4","volume":"48","author":"Boeck","year":"2013","unstructured":"Boeck S et al (2013) KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. J Gastroenterol 48:544\u2013548","journal-title":"J Gastroenterol"},{"key":"1865_CR33","doi-asserted-by":"crossref","unstructured":"Del Chiaro M et al (2013) European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. doi: 10.1016\/j.dld.2013.01.010","DOI":"10.1016\/j.dld.2013.01.010"},{"key":"1865_CR34","doi-asserted-by":"crossref","first-page":"21188","DOI":"10.1073\/pnas.1118046108","volume":"108","author":"Wu","year":"2011","unstructured":"Wu J et al (2011) Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci 108:21188\u201321193","journal-title":"Proc Natl Acad Sci"},{"key":"1865_CR35","doi-asserted-by":"crossref","first-page":"ra66","DOI":"10.1126\/scitranslmed.3002669","volume":"3","author":"Wu","year":"2011","unstructured":"Wu J et al (2011) Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3(92):ra66\u201392ra66","journal-title":"Sci Transl Med"},{"key":"1865_CR36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/gutjnl-2012-303108","volume":"62","author":"Canto","year":"2012","unstructured":"Canto MI et al (2012) International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62:339\u2013347","journal-title":"Gut"},{"key":"1865_CR37","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1158\/1078-0432.CCR-12-0035","volume":"18","author":"Matthaei","year":"2012","unstructured":"Matthaei H et al (2012) miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res 18:4713\u20134724","journal-title":"Clin Cancer Res"},{"key":"1865_CR38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MPA.0b013e31822a27db","volume":"41","author":"Kimura","year":"2012","unstructured":"Kimura W et al (2012) Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas 41:380\u2013387","journal-title":"Pancreas"},{"key":"1865_CR39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/cncr.23346","volume":"114","author":"Belsley","year":"2008","unstructured":"Belsley NA, Pitman MB, Lauwers GY et al (2008) Serous cystadenoma of the pancreas: limitations and pitfalls of endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer 114:102\u2013110","journal-title":"Cancer"},{"key":"1865_CR40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000346911","volume":"57","author":"Collins","year":"2013","unstructured":"Collins BT (2013) Serous cystadenoma of the pancreas with endoscopic ultrasound fine needle aspiration biopsy and surgical correlation. Acta Cytol 57:241\u2013251","journal-title":"Acta Cytol"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-013-1865-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-013-1865-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-013-1865-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:06:37Z","timestamp":1559041597000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-013-1865-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":40,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s00292-013-1865-z","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}